par Suarez-Carmona, Meggy
;Halama, Niels
Référence Trends in Cancer, 10, 12, page (1093-1094)
Publication Publié, 2024-12-01
;Halama, NielsRéférence Trends in Cancer, 10, 12, page (1093-1094)
Publication Publié, 2024-12-01
Article révisé par les pairs
| Résumé : | Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit. |



